| Bioactivity | Licogliflozin is a sodium glucose cotransporter (SGLT1 and SGLT2) inhibitor. | ||||||||||||
| Target | SGLT1, SGLT2 | ||||||||||||
| Invitro | Licogliflozin (LIK066) is a non-anti-fibrotic treatment agent for non-alcoholic steatohepatitis (NASH). | ||||||||||||
| Name | Licogliflozin | ||||||||||||
| CAS | 1291094-73-9 | ||||||||||||
| Formula | C23H28O7 | ||||||||||||
| Molar Mass | 416.46 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Monica A. Konerman, et al. Overview of Clinical Treatment Trials for NASH.Curr Hepatol Rep. 2017 Dec;16(4): 366-373. |